{
  "drugid": "RxNorm:8687",
  "drugname": "primaquine",
  "guidelinename": "G6PD",
  "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-g6pd/",
  "guidelinepharmgkbids": [
    "PA166119846"
  ],
  "citations": [
    {
      "pmid": "36049896",
      "title": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.",
      "authors": [
        "Gammal Roseann S",
        "Pirmohamed Munir",
        "Somogyi Andrew A",
        "Morris Sarah A",
        "Formea Christine M",
        "Elchynski Amanda L",
        "Oshikoya Kazeem A",
        "McLeod Howard L",
        "Haidar Cyrine E",
        "Whirl-Carrillo Michelle",
        "Klein Teri E",
        "Caudle Kelly E",
        "Relling Mary V"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2022
    }
  ],
  "recommendations": [
    {
      "implications": {
        "G6PD": "Unknown risk of acute hemolytic anemia"
      },
      "drugrecommendation": "To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",
      "classification": "Moderate",
      "phenotypes": {
        "G6PD": "Indeterminate"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "G6PD": "Indeterminate"
      },
      "comments": null,
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "G6PD": "Variable risk of acute hemolytic anemia"
      },
      "drugrecommendation": "To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",
      "classification": "Moderate",
      "phenotypes": {
        "G6PD": "Variable"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "G6PD": "Variable"
      },
      "comments": "Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one nondeficient (class IV) and one deficient (class Iâ€“III) allele may display a normal or a deficient phenotype; an enzyme activity test is needed to guide treatment in such cases.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "G6PD": "High risk of acute of acute exacerbation of chronic hemolysis"
      },
      "drugrecommendation": "Avoid primaquine",
      "classification": "Strong",
      "phenotypes": {
        "G6PD": "Deficient with CNSHA"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "G6PD": "Deficient with CNSHA"
      },
      "comments": "The strength of evidence among patients with the G6PD Deficient phenotype provides strong rationale to also avoid primaquine in the setting of the more severe G6PD Deficient with CNSHA phenotype.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "G6PD": "High risk of acute hemolytic anemia with standard (or higher than standard) anti-relapse dosages for Plasmodium vivax or Plasmodium ovale of 0.25-0.5 mg/kg daily for 14 days"
      },
      "drugrecommendation": "Avoid primaquine, except in the following cases where established expert consensus guidelines for the treatment of malaria should be followed: (1) Treating Plasmodium vivax or Plasmodium ovale malaria for radical cure of liver-stage infections: 0.75 mg/kg once weekly x8 weeks (WHO) or 45 mg once weekly x8 weeks (CDC) - with close monitoring for hemolysis; (2) Treating Plasmodium falciparum malaria by using primaquine single dose as a gametocytocide at 0.25 mg/kg (WHO) - without need for monitoring for hemolysis.",
      "classification": "Strong",
      "phenotypes": {
        "G6PD": "Deficient"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "G6PD": "Deficient"
      },
      "comments": "Dosing recommendations for primaquine in patients with G6PD deficiency are derived from the malaria treatment guidelines issued by the World Health Organization and the U.S. Centers for Disease Control and Prevention.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "G6PD": "Low risk of acute hemolytic anemia"
      },
      "drugrecommendation": "No reason to avoid based on G6PD status",
      "classification": "Strong",
      "phenotypes": {
        "G6PD": "Normal"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "G6PD": "Normal"
      },
      "comments": null,
      "population": "general",
      "genotypes": null
    }
  ],
  "genes": [
    "G6PD"
  ],
  "notesonusage": null,
  "cpicVersion": "v1.22.2",
  "source": "CPIC"
}